Haleh Saber

2PUBLICATIONS
39CO-AUTHORS
Gene and molecular therapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

|Sep 05, 2025
FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

Michael I Barbato, Amy K Barone, Stephanie L Aungst

|Jan 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma.

Sonia Singh, Diana Bradford, Somak Chatterjee

Pageof 1